Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
20 02 2021
20 02 2021
Historique:
pubmed:
16
9
2020
medline:
16
9
2021
entrez:
15
9
2020
Statut:
ppublish
Résumé
We report the long-term findings and final analysis of a pivotal multicenter trial of ibrutinib monotherapy in previously treated patients with Waldenström macroglobulinemia (WM). Sixty-three symptomatic patients with median prior therapies of two (range, one to nine therapies), of whom 40% were refractory to their previous therapy, received ibrutinib at 420 mg/d. Dose reduction was permitted for toxicity. The median follow-up was 59 months, and overall and major response rates were 90.5% and 79.4%, respectively. At best response, median serum immunoglobulin M declined from 3,520 to 821 mg/dL, bone marrow disease involvement declined from 60% to 20%, and hemoglobin rose from 10.3 to 14.2 g/dL ( Ibrutinib is highly active and produces long-term disease control in previously treated patients with WM. Treatment is tolerable. Response depth, time to major response, and PFS are impacted by
Identifiants
pubmed: 32931398
doi: 10.1200/JCO.20.00555
pmc: PMC8078354
doi:
Substances chimiques
Piperidines
0
ibrutinib
1X70OSD4VX
Adenine
JAC85A2161
Banques de données
ClinicalTrials.gov
['NCT01614821']
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
565-575Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA100707
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Blood Adv. 2018 Nov 13;2(21):2937-2946
pubmed: 30401751
Haematologica. 2017 Nov;102(11):e452-e455
pubmed: 28798070
Blood. 2014 May 1;123(18):2791-6
pubmed: 24553177
Blood Adv. 2019 Jun 25;3(12):1799-1807
pubmed: 31196847
Am J Hematol. 2016 Jun;91(6):E312-3
pubmed: 26994323
Clin Cancer Res. 2016 Mar 15;22(6):1480-8
pubmed: 26490317
Br J Haematol. 2015 Mar;168(5):701-7
pubmed: 25371371
Semin Oncol. 2003 Apr;30(2):116-20
pubmed: 12720119
N Engl J Med. 2012 Aug 30;367(9):826-33
pubmed: 22931316
Blood. 2013 Aug 15;122(7):1222-32
pubmed: 23836557
J Clin Oncol. 2018 Sep 20;36(27):2755-2761
pubmed: 30044692
N Engl J Med. 2018 Jun 21;378(25):2399-2410
pubmed: 29856685
Lancet Oncol. 2017 Feb;18(2):241-250
pubmed: 27956157
Blood Adv. 2017 Nov 28;1(25):2483-2485
pubmed: 29296898
Br J Haematol. 2013 Jan;160(2):171-6
pubmed: 23150997
Blood. 2013 Mar 14;121(11):2051-8
pubmed: 23321251
Blood. 2014 Mar 13;123(11):1637-46
pubmed: 24366360
Blood Adv. 2017 Nov 28;1(25):2486-2490
pubmed: 29296899
Blood Cancer J. 2020 Jan 31;10(1):12
pubmed: 32005797
Blood Adv. 2017 Sep 08;1(20):1739-1748
pubmed: 29296820
N Engl J Med. 2015 Apr 9;372(15):1430-40
pubmed: 25853747
Semin Oncol. 2003 Apr;30(2):110-5
pubmed: 12720118
Leukemia. 2015 Jan;29(1):169-76
pubmed: 24912431
N Engl J Med. 2015 Aug 6;373(6):584-6
pubmed: 26244327
Blood. 2014 Jun 26;123(26):4120-31
pubmed: 24711662
Blood. 2016 Jun 23;127(25):3237-52
pubmed: 27143257
J Clin Oncol. 2010 May 1;28(13):2227-32
pubmed: 20368570
Haematologica. 2017 Oct;102(10):1796-1805
pubmed: 28751558
Br J Haematol. 2016 Mar;172(5):735-44
pubmed: 26659815
Blood. 2016 Sep 8;128(10):1321-8
pubmed: 27432877
Lancet Haematol. 2020 Feb;7(2):e112-e121
pubmed: 31866281
Haematologica. 2017 Dec;102(12):2077-2085
pubmed: 28983055
Blood. 2009 Apr 30;113(18):4163-70
pubmed: 19196866